Risk of Delayed or Failed Commercialization of Research and Development
First written in FY2016. 26 of 28 entries say "Restated". Latest entry: FY2024.
The whole theme swung hardest in 2026: 14 of 29 companies on the "Worse" side.
0 other companies' latest entry also says "Dropped".
- FY2024DroppedAnnual reportThe risk disclosure in this business and other risks section does not separately mention the previously disclosed possibility that R&D may not reach commercialization or may take time.
- FY2024-Q3RestatedAnnual report
「There were no material changes in the status of the Group’s R&D activities during the nine months ended December 31, XXXX.」
The company states that there are no material changes to its R&D activities regarding existing risks, including the possibility that R&D may not reach commercialization or may be delayed. - FY2024-Q2RestatedAnnual report
「There were no material changes in the status of the Group’s R&D activities during the six months ended June 30, XXXX.」
The company states that there are no material changes to its R&D activities regarding existing risks, including the possibility that R&D may not reach commercialization or may be delayed. - FY2024-Q1RestatedAnnual report
「R&D expenses for the first quarter of the fiscal year were ¥1,272 million. There were no material changes in the status of the Group's R&D activities during the first quarter.」
The company recorded R&D expenses of ¥1,272 million and states that there were no material changes in its R&D activities. - FY2023-Q3RestatedAnnual report
「There were no material changes in the status of the Group’s R&D activities during the nine months ended December 31, XXXX.」
The company states that there are no material changes to the existing risks, including the possibility that R&D may not reach commercialization or may take time to reach commercialization. - FY2023-Q2RestatedAnnual report
「There were no material changes in the status of the Group’s R&D activities during the six months ended June 30, XXXX.」
The company states that there are no material changes to the existing risks, including the possibility that R&D may not reach commercialization or may take time to reach commercialization. - FY2023-Q1RestatedAnnual report
「There were no material changes in the status of the Group’s R&D activities during the three months ended March 31, XXXX.」
The company states that there are no material changes to its R&D activities regarding existing risks, including the possibility that R&D may not reach commercialization or may be delayed. - FY2022RestatedAnnual report
「The Group's R&D activities cover the semiconductor-related, measurement and weighing equipment, and medical and healthcare equipment fields and are all aimed at commercialization. However, there is a possibility that commercialization may not be achieved or that it may take time to reach commercialization.」
The Group invested ¥4,874 million in R&D, equivalent to 9.4% of net sales, and continued R&D including in the semiconductor-related field, while maintaining its disclosure of the risk that commercialization may not be achieved or may be delayed. - FY2022-Q3RestatedAnnual report
「There were no significant changes in the status of research and development activities of our group during the cumulative third quarter consolidated accounting period.」
The company states that there are no material changes to the existing risks, including the possibility that R&D may not reach commercialization or may take time to reach commercialization. - FY2022-Q1RestatedAnnual report
「There were no material changes in the status of the Group’s research and development activities during the first three months of the fiscal year.」
The company states that there are no material changes to the existing risks, including the possibility that R&D may not reach commercialization or may take time. - FY2021RestatedAnnual report
「Total R&D expenses for the fiscal year were ¥5,065 million, equivalent to 10.5% of consolidated net sales. As an R&D-driven company, the Group actively invests resources in research and development. The Group's R&D activities cover the measurement and weighing equipment and medical and healthcare equipment fields and are all aimed at commercialization. However, there is a possibility that commercialization may not be achieved or that it may take time to reach commercialization.」
The disclosure continues to describe active R&D investment and the possibility that commercialization may not be achieved or may take time. - FY2021-Q3RestatedAnnual report
「During the third quarter of the fiscal year, there were no material changes in the occurrence of major risks that management recognizes as potentially having a material impact on the financial position, operating results or cash flows of the consolidated companies, among the matters relating to the business conditions, financial position and other matters described in this quarterly report, or in the "Business and Other Risks" described in the annual securities report for the previous fiscal year.」
The company states that there are no material changes to the existing risks, including the possibility that R&D may not reach commercialization or may take time. - FY2021-Q2RestatedAnnual report
「There were no material changes in the status of the group's R&D activities during the first half of the current consolidated cumulative period.」
The company states that there are no material changes to the existing risks, including the possibility that R&D may not reach commercialization or may take time to reach commercialization. - FY2021-Q1RestatedAnnual report
「During the first quarter of the fiscal year, there were no material changes in the occurrence of major risks that management recognizes as potentially having a material impact on the financial position, operating results or cash flows of the consolidated companies, among the matters relating to the business conditions, financial position and other matters described in this quarterly report, or in the "Business and Other Risks" described in the annual securities report for the previous fiscal year.」
The company states that there are no material changes to the existing risks, including the possibility that R&D may not reach commercialization or may take time to reach commercialization. - FY2020RestatedAnnual report
「Total R&D expenses for the fiscal year were ¥5,000 million, equivalent to 10.2% of consolidated net sales. As an R&D-driven company, the Group actively invests resources in research and development. The Group's R&D activities cover the measurement and weighing equipment and medical and healthcare equipment fields and are all aimed at commercialization. However, there is a possibility that commercialization may not be achieved or that it may take time to reach commercialization.」
The company continues to invest in R&D and to disclose the possibility that commercialization may not be achieved or may take time. - FY2020-Q3RestatedAnnual report
「No new business or other risks arose during the nine months ended [the current third quarter]. There have also been no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The company states that there are no material changes regarding the possibility that R&D may not reach commercialization or that commercialization may take time. - FY2020-Q2RestatedAnnual report
「During the cumulative second quarter of the current consolidated fiscal year, there were no newly arising business or other risks. In addition, there were no material changes to the business or other risks described in the annual securities report for the previous fiscal year.」
The company states that there are no material changes regarding the possibility that R&D may not reach commercialization or that commercialization may take time. - FY2020-Q1RestatedAnnual report
「During the first quarter of the current consolidated fiscal year, there were no newly arising business or other risks. In addition, there were no material changes to the business or other risks described in the annual securities report for the previous fiscal year.」
The company states that there are no material changes regarding the possibility that R&D may not reach commercialization or that commercialization may take time. - FY2019RestatedAnnual report
「Total R&D expenses for the fiscal year were ¥4,898 million, equivalent to 10.1% of consolidated net sales. As an R&D-driven company, the Group actively invests resources in research and development. The Group's R&D activities cover the measurement and weighing equipment and medical and healthcare equipment fields and are all aimed at commercialization. However, there is a possibility that commercialization may not be achieved or that it may take time to reach commercialization.」
The disclosure continues to describe ongoing R&D investment and the possibility that commercialization may not be achieved or may take time. - FY2019-Q3RestatedAnnual report
「No new business or other risks arose during the nine months ended [the current third quarter]. There have also been no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The company states that there are no material changes regarding the possibility that R&D may not reach commercialization or may take time to reach commercialization. - FY2019-Q2RestatedAnnual report
「During the cumulative second quarter of the current consolidated fiscal year, there were no newly arising business or other risks. In addition, there were no material changes to the business or other risks described in the annual securities report for the previous fiscal year.」
The company states that there are no material changes regarding the possibility that R&D may not reach commercialization or that commercialization may take time. - FY2019-Q1RestatedAnnual report
「During the first quarter of the current consolidated fiscal year, there were no newly arising business or other risks. In addition, there were no material changes to the business or other risks described in the annual securities report for the previous fiscal year.」
The company states that there are no material changes regarding the possibility that R&D may not reach commercialization or may take time to reach commercialization. - FY2018RestatedAnnual report
「The Group's R&D activities cover the measurement and weighing equipment and medical and healthcare equipment fields and are all aimed at commercialization. However, there is a possibility that commercialization may not be achieved or that it may take time to reach commercialization.」
The Group continues R&D in both business fields while maintaining the disclosure regarding the possibility that commercialization may not be achieved or may take time. R&D expenses were ¥4,676 million, equivalent to 10.6% of net sales. - FY2018-Q3RestatedAnnual report
「No new business or other risks arose during the nine months ended [the current third quarter]. There have also been no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The company states that there are no material changes regarding the possibility that R&D may not reach commercialization or that commercialization may take time. - FY2018-Q2RestatedAnnual report
「During the cumulative second quarter of the current consolidated fiscal year, there were no newly arising business or other risks. In addition, there were no material changes to the business or other risks described in the annual securities report for the previous fiscal year.」
The company states that there are no material changes regarding the possibility that R&D may not reach commercialization or that commercialization may take time. - FY2018-Q1RestatedAnnual report
「During the first quarter of the current consolidated fiscal year, there were no newly arising business or other risks. In addition, there were no material changes to the business or other risks described in the annual securities report for the previous fiscal year.」
The company states that there are no material changes regarding the possibility that R&D may not reach commercialization or that commercialization may take time. - FY2017RestatedAnnual report
「Total R&D expenses for the fiscal year were ¥4,444 million, equivalent to 11.1% of consolidated net sales. As an R&D-driven company, the Group actively invests resources in research and development. The Group's R&D activities cover the measurement and weighing equipment and medical and healthcare equipment fields and are all aimed at commercialization. However, there is a possibility that commercialization may not be achieved or that it may take time to reach commercialization.」
The disclosure continues to describe active investment in R&D and the possibility that commercialization may not be achieved or may take time. - FY2016First statedAnnual report
「Total R&D expenses for the fiscal year were ¥4,653 million, equivalent to 11.6% of consolidated net sales. As an R&D-driven company, the Group actively invests resources in research and development. The Group's R&D activities cover the measurement and weighing equipment and medical and healthcare equipment fields and are all aimed at commercialization. However, there is a possibility that commercialization may not be achieved or that it may take time to reach commercialization.」
The disclosure specifies the scale of R&D investment and explicitly states the possibility that commercialization may not be achieved or may take time.